Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    180 Life Sciences Corp. (ATNF)

    Price:

    7.04 USD

    ( - -0.57 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    ATNF
    Name
    180 Life Sciences Corp.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    7.040
    Market Cap
    1.077B
    Enterprise value
    -2.765M
    Currency
    USD
    Ceo
    Lloyd Blair Jordan
    Full Time Employees
    4
    Ipo Date
    2017-06-27
    City
    Palo Alto
    Address
    Building 4

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    60.497B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.551B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.373B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -1.445
    P/S
    3.924k
    P/B
    2.472
    Debt/Equity
    0.263
    EV/FCF
    -117.883
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    3.915k
    Earnings yield
    -0.692
    Debt/assets
    0.132
    FUNDAMENTALS
    Net debt/ebidta
    0.085
    Interest coverage
    -230.446
    Research And Developement To Revenue
    12.983
    Intangile to total assets
    0.711
    Capex to operating cash flow
    -0.000
    Capex to revenue
    0.000
    Capex to depreciation
    0.001
    Return on tangible assets
    -2.977
    Debt to market cap
    0.004
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    2.039
    P/CF
    -12.720
    P/FCF
    -341.028
    RoA %
    -85.924
    RoIC %
    -92.547
    Gross Profit Margin %
    35.437
    Quick Ratio
    0.580
    Current Ratio
    0.580
    Net Profit Margin %
    -9.679k
    Net-Net
    -0.544
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.553
    Revenue per share
    0.017
    Net income per share
    -1.613
    Operating cash flow per share
    -0.553
    Free cash flow per share
    -0.553
    Cash per share
    0.389
    Book value per share
    0.943
    Tangible book value per share
    -0.393
    Shareholders equity per share
    0.943
    Interest debt per share
    0.252
    TECHNICAL
    52 weeks high
    17.750
    52 weeks low
    0.658
    Current trading session High
    7.240
    Current trading session Low
    6.290
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    -87.0%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -5.3900312999999995%
    P/E
    -0.056
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -4406.231%
    P/E
    -0.803
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.868
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0.6504065%
    Payout Ratio
    0%
    P/E
    2.153
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.709
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.573
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.827
    DESCRIPTION

    1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

    NEWS
    https://images.financialmodelingprep.com/news/stock-market-today-sp-500-nasdaq-100-futures-trade-20250815.jpg
    Stock Market Today: S&P 500, Nasdaq 100 Futures Trade Mixed— UnitedHealth, 180 Life Sciences, Intel In Focus

    benzinga.com

    2025-08-15 05:55:59

    U.S. stock futures were fluctuating on Friday following Thursday's mixed moves. Futures of major benchmark indices were mixed.

    https://images.financialmodelingprep.com/news/palantir-cofounder-peter-thiel-buys-into-crypto-firm-as-20250813.jpg
    Palantir co-founder Peter Thiel buys into crypto firm as stock soars 250%

    finbold.com

    2025-08-13 05:07:08

    Shares of 180 Life Sciences Corp. (NASDAQ: ATNF) surged 206.59% on Tuesday to close at $10.24, after regulatory filings revealed that billionaire tech investor Peter Thiel had acquired a 7.5% stake in the company.

    https://images.financialmodelingprep.com/news/180-life-sciences-ethzilla-holds-82186-eth-20250812.jpg
    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    prnewswire.com

    2025-08-12 08:00:00

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif. , Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million.

    https://images.financialmodelingprep.com/news/180-life-sciences-announces-closing-of-private-offering-of-20250811.jpg
    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    prnewswire.com

    2025-08-11 08:00:00

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif. , Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025.

    https://images.financialmodelingprep.com/news/180-life-sciences-closes-425-million-private-placement-to-20250804.jpg
    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    prnewswire.com

    2025-08-04 22:30:00

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif. , Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase price of $2.65 per share.

    https://images.financialmodelingprep.com/news/180-life-sciences-announce-an-upsized-425-million-private-20250729.jpg
    180 Life Sciences Announce an Upsized $425 Million Private Placement to Establish an Ether Treasury Reserve Led by Consortium of Digital Asset Leaders to Launch ETHZilla

    prnewswire.com

    2025-07-29 09:26:00

    180 Life Sciences announces entry into PIPE funding documents to raise $425 million in gross proceeds to launch next generation Ethereum treasury strategy and planned rebranding to ETHZilla PALO ALTO, Calif. , July 29, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF) (the "Company" or "180 Life Sciences") today announced that it plans to adopt a treasury policy under which the principal holding in its treasury reserve will be Ether ("ETH"), the native digital asset of Ethereum.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-announces-strengthening-of-legacy-intellectual-20250701.jpg
    180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

    accessnewswire.com

    2025-07-01 07:30:00

    PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming sector, today announced two significant value enhancements to its existing, legacy intellectual property ("IP") portfolio-reinforcing part of the Company's strategy relating to continuing to build shareholder value through scientific innovation and patent protection for legacy IP assets. These new developments reflect 180's ongoing efforts to secure strong IP rights for its novel IP, while also positioning these assets for potential future partnering, licensing, or strategic transactions aimed at maximizing value for shareholders while the Company focuses on the global iGaming sector.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-announces-notice-of-allowance-for-20250501.jpg
    180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

    accessnewswire.com

    2025-05-01 09:30:00

    PALO ALTO, CA / ACCESS Newswire / May 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), an innovative media and entertainment company focused on the global iGaming sector, with certain legacy biotechnology intellectual property assets, today announced that the United States Patent and Trademark Office ("USPTO") has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction ("POCD").

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-announces-share-repurchase-20250430.jpg
    180 Life Sciences Corp. Announces Share Repurchase

    accessnewswire.com

    2025-04-30 08:30:00

    PALO ALTO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences," the "Company," "we," or "us") today announced that it has entered into a Settlement and Mutual Release Agreement (the "Agreement") with Elray Resources, Inc. ("Elray") and Luxor Capital, LLC ("Luxor"). The Agreement strengthens and simplifies the Company's capital structure through a significant repurchase of shares.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-announces-pricing-of-29-million-20241227.jpg
    180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

    accesswire.com

    2024-12-27 09:00:00

    PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-regains-full-compliance-with-nasdaq-20241212.jpg
    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    accesswire.com

    2024-12-12 08:00:00

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-announces-the-appointment-of-stephen-20241204.jpg
    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    accesswire.com

    2024-12-04 08:00:00

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024. Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-appoints-mr-jay-goodman-to-20241029.jpg
    180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

    accesswire.com

    2024-10-29 08:00:00

    PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-interim-ceo-blair-jordan-issues-20241016.jpg
    180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

    accesswire.com

    2024-10-16 08:00:00

    PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan. Dear Stockholders: We are excited to announce that 180 is planning to strategically enter into the online gaming industry, utilizing its newly acquired "back-end" gaming platform, which incorporates blockchain technology and full cryptocurrency operability (the "Gaming Technology Platform").

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-regains-compliance-with-nasdaqs-minimum-20241009.jpg
    180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector

    accesswire.com

    2024-10-09 08:30:00

    PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.

    https://images.financialmodelingprep.com/news/180-life-sciences-corp-corporate-updates-20241003.jpg
    180 Life Sciences Corp. - Corporate Updates

    accesswire.com

    2024-10-03 08:30:00

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet PALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives. CORPORATE UPDATE HIGHLIGHTS: Company shifts focus and enters global iGaming market - completes a significant technology acquisition Expected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 million Positive Study Results on CBD Pill Forms - 180 achieves promising study results showing faster absorption and improved bioavailability for its new CBD pill formulation Strengthened Balance Sheet - Company enhances its financial position by settling meaningful legacy liabilities at substantial discounts, improving its flexibility for future growth while at the same time resolving certain legacy litigation matters "We believe that this acquisition is a pivotal moment for the Company," said Blair Jordan, Interim CEO of 180, who continued, "We believe this transaction not only satisfies Nasdaq's minimum stockholder equity requirements for continued listing, but also sets the stage for the Company's entry into the dynamic and fast-growing global iGaming industry.